Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

Modern network science has revealed fundamental aspects of normal brain-network
organization, such as small-world and scale-free patterns, hierarchical modularity, hubs and …

Abstract Characterization of the genetic landscape of Alzheimer's disease (AD) and related
dementias (ADD) provides a unique opportunity for a better understanding of the associated …

Introduction Several studies have reported alterations in gut microbiota composition of
Alzheimer's disease (AD) patients. However, the observed differences are not consistent …

Introduction Studies using different assays and technologies showed highly promising
diagnostic value of plasma phosphorylated (P-) tau levels for Alzheimer's disease (AD). We …

Introduction We estimated the age-specific duration of the preclinical, prodromal, and
dementia stages of Alzheimer's disease (AD) and the influence of sex, setting …

Background Blood-based biomarkers for Alzheimer's disease (AD) might facilitate
identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation …

Introduction In this multicenter study on subjective cognitive decline (SCD) in community-
based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease …

Objective We investigated the association of plasma amyloid beta (Abeta) 40, Abeta42, and
total tau (tTau) with the presence of Alzheimer pathological changes in cognitively normal …

The global impact of Alzheimer's disease (AD) continues to increase, and focused efforts are
needed to address this immense public health challenge. National leaders have set a goal …